Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | LPL | P06858 | 2/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13703299 | 0.85 | LPL (0.40) | LPLLIPGPPARGPPARA | |
| SCHEMBL14692925 | 0.84 | CYSLTR2 (0.39) | LPLLIPG | |
| SCHEMBL13703030 | 0.84 | CYSLTR2 (0.39) | LPLLIPG | |
| SCHEMBL9205158 | 0.82 | TDP1 (0.49) | — | |
| SCHEMBL22861338 | 0.82 | TDP1 (0.49) | — | |
| SCHEMBL13636301 | 0.81 | HTR2C (0.38) | HTR1ALPLLIPGPPARGPPARA | |
| SCHEMBL13636267 | 0.81 | HTR2C (0.38) | HTR1ALPLLIPGPPARGPPARA | |
| SCHEMBL13636300 | 0.81 | HTR2C (0.38) | HTR1ALPLLIPGPPARGPPARA | |
| SCHEMBL28827740 | 0.81 | AGXT (0.47) | HTR1AFFAR4AGXTHDAC1HTR7 | |
| SCHEMBL22281732 | 0.80 | IDO1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | HTR1A 4040/4885LPL 2978/4885LIPG 1914/4885 |
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | HTR1A 4040/4885LPL 2978/4885LIPG 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.